Bellerophon Therapeutics

117 articles about Bellerophon Therapeutics

• Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

  6/5/2023

  Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INOpulse® for the treatment of fibrotic Interstitial Lung Disease (fILD).

• Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results

  5/15/2023

  Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2023.

• Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseasePivotal top-line data readout expected in mid-2023

  5/11/2023

  Bellerophon Therapeutics, Inc. today announced that the last patient has completed blinded treatment in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD).

• Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results

  3/31/2023

  Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2022.

• Bellerophon Therapeutics Announces $5 Million Registered Direct Offering

  3/6/2023

  Bellerophon Therapeutics, Inc. today announced that it has entered into a subscription agreement with a life sciences-focused institutional investor to sell, in a registered direct offering, 718,474 shares of common stock.

• Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung Disease

  2/9/2023

  Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced clearance of its Investigational New Drug (IND) application from the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) to conduct a Phase 3 clinical trial to support the registration of INOpulse® for the treatment of fibrotic interstitial lung disease (fILD) in China.

• Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

  1/18/2023

  Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced that the last patient has been enrolled in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD).

• Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciences

  1/5/2023

  Bellerophon Therapeutics, Inc. announced that it has entered into a license agreement for the development and commercialization of INOpulse® with Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China.

• Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results

  11/14/2022

  Bellerophon Therapeutics, Inc. today provided a clinical program update and reported financial results for the third quarter ended September 30, 2022.

• 

  FDA Review: Amylyx, Sarepta, Sanofi-Regeneron and More

  9/30/2022

  The FDA had a busy week, approving drugs, greenlighting clinical trials and other regulatory activities for Immuneering, Amylyx, Sarepta, Sanofi, and Regeneron and more. 

• Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

  9/27/2022

  Bellerophon Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s proposal to reduce the study size for its ongoing registrational REBUILD Phase 3 trial of INOpulse® for the treatment of fibrotic Interstitial Lung Disease (fILD).

• Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results

  8/15/2022

  Bellerophon Therapeutics, Inc. today provided a clinical program update and reported financial results for the second quarter ended June 30, 2022.

• Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference

  5/12/2022

  Bellerophon Therapeutics, Inc. announced a poster presentation at the upcoming American Thoracis Society 2022 International Conference, being held May 13-18, 2022, in San Francisco, CA.

• Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results

  5/11/2022

  Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2022.

• Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results

  3/31/2022

  Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2021.

• Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

  1/10/2022

  Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced that Naseem Amin, M.D., Chairman of Bellerophon’s Board of Directors, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.

• Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis

  12/17/2021

  Bellerophon Therapeutics, Inc. oday announced positive top-line data from a recently completed Phase 2 dose escalation study (PULSE-PHPF-002) evaluating the acute hemodynamic benefit of INOpulse® via right heart catheterization for the treatment of pulmonary hypertension associated with sarcoidosis (PH-Sarc).

• Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results

  11/15/2021

  Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2021.

• Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  Bellerophon Therapeutics, Inc. announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021.

• Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results

  8/5/2021

  Bellerophon Therapeutics, Inc. today provided a clinical program update and reported financial results for the second quarter ended June 30, 2021.